Innovative UK SME GeneFirst and University of Leeds win £1.4M NIHR grant to clinically validate the use of a novel NGS based technology in bowel cancer screening
GeneFirst has teamed up with the Division of Pathology and Data Analytics at the University of Leeds to investigate the clinical utility of a novel NGS technology, Adaptor Temple Oligo-Mediated Sequencing (ATOM-Seq™), in bowel cancer screening and diagnostics. As the recipient of the highly competitive Invention for Innovation (i4i) funding from the National Institute of Health (NIHR), the aim of the project is to determine whether a sequencing-based assay for bowel cancer, testing either faecal tumour DNA or blood-derived cf/ctDNA (cell free/circulating tumour DNA), would be suited for the implementation into clinical use. [...]
NEW publication on the utility of GeneFirst’s ATOM-Seq (TM) NGS library preparation technology for use with cfDNA and cfRNA
GeneFirst Limited is proud to have the recent paper titled Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-Sensitive UMI-based NGS librarypreparation technology for use with cfDNA and cfRNA accepted for publication by Scientific Reports. The paper is the [...]
NEW publication on the analytical performance of Papilloplex HR-HPV
The accurate detection and genotyping of high-risk human papillomavirus (HR-HPV) is critical for cervical cancer screening and epidemiological investigations. GeneFirst Papilloplex® HRHPV is a new CE-IVD marked real-time PCR test, based on patented Multiplex Probe Amplification (MPA) technology. Papilloplex® HR-HPV provides the simultaneous detection and differentiation of 14 HR-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68a/b) in a single closed-tube reaction ensuring rapid, cost effective and contamination free results. In this study, the analytical performance characteristics in terms of the assay’s sensitivity, specificity, range, reproducibility and cross-reactivity were evaluated. Papilloplex® HR-HPV provided sensitive detection and differentiation of 14 HR-HPV types with highly reproducible results. The differential HR-HPV specificity and sensitivity was further confirmed through the participation in the WHO HPV Laboratory Network Proficiency Study (2014). Overall, GeneFirst Papilloplex® HR-HPV assay demonstrated a robust analytical performance with reproducible and reliable results in the detection of HR-HPV genotypes.
GeneFirst wins €2.9m Horizon 2020 grant to deliver predictive diagnostic panel for HPV infections evolving into cervical cancer
Oxford, UK. GeneFirst Limited, the leader in delivering innovative solutions for HPV testing today announces the award of a €2.9 million up-front grant from the SME Instrument of the European Commission’s Horizon 2020 Programme to develop a predictive assay panel that can discriminate those hrHPV infections at increased risk of disease progression. This work will be conducted with GeneFirst’s joint collaborator, Hiantis S.r.l, based in Milan, Italy, who has extensive experience in clinical and laboratory research.
GeneFirst wins second major Innovate UK competitive grant to improve cancer treatment using its ATOM-seq™ NGS technology
Oxford, UK. GeneFirst Limited, the leader in delivering Next Generation Sequencing solutions for liquid biopsy testing, today announces the award of a 12-month grant of £457,000 from Innovate UK’s Open Programme Round 3 to continue development of DNA sequencing technology to improve cancer treatment through better detection of cancer mutations in blood.
GeneFirst wins Innovate UK’s Shanghai-UK competition for the development of non-invasive test for cancer
Oxford, UK. GeneFirst Limited, the leader in delivering Next Generation Sequencing solutions for liquid biopsy testing, today announces the award of a two year grant of £350,000 from Innovate UK’s Shanghai-UK Challenge Programme to develop a non-invasive test for cancer gene mutations with Fosun Med-Tech.
The Innovate UK funding is a joint UK-Shanghai competition to identify new and novel products, processes or services drawn from any technology, engineering or industrial area. Under this highly competitive grant, GeneFirst will use its leading and proprietary ATOM-seq™ technology to deliver an NGS assay panel to detect cancer gene mutations in liquid biopsy, enabling clinically relevant cancer genotyping by non-invasive means.